CAR-T cells + cytotoxic T lymphocytes + dendritic cell vaccine (Shenzhen Geno-Immune Medical Institute)

This combination therapy, developed by the Shenzhen Geno-Immune Medical Institute, is an investigational integrated immunotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia (B-ALL). The approach sequentially combines three distinct cellular components: multi-antigen-targeted chimeric antigen receptor (CAR) T cells, engineered antigen-specific cytotoxic T lymphocytes (CTLs), and an immune-modified dendritic cell vaccine (DCvac). The CAR-T cells are intended to provide rapid tumor debulking, while the CTLs and DCvac work synergistically to maintain long-term immune surveillance and eradicate minimal residual disease. The primary goal of this protocol is to achieve a Next-Generation Sequencing (NGS) Minimal Residual Disease (MRD) negative status, which is a key predictor of long-term remission and survival without the need for further intensive treatments like hematopoietic stem cell transplantation.

Other names

CAR-T/CTL/DCvac combination therapyNGS-MRD Evaluation of CAR-T, CTL, and DCvac in B-ALL